ID   UBA1_HUMAN              Reviewed;        1058 AA.
AC   P22314; Q5JRR8; Q96E13;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   25-OCT-2002, sequence version 3.
DT   10-MAY-2017, entry version 197.
DE   RecName: Full=Ubiquitin-like modifier-activating enzyme 1;
DE            EC=6.2.1.45 {ECO:0000305|PubMed:1447181};
DE   AltName: Full=Protein A1S9;
DE   AltName: Full=Ubiquitin-activating enzyme E1;
GN   Name=UBA1; Synonyms=A1S9T, UBE1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND PATHWAY.
RX   PubMed=1606621;
RA   Ayusawa D., Kaneda S., Itoh Y., Yasuda H., Murakami Y., Sugasawa K.,
RA   Hanaoka F., Seno T.;
RT   "Complementation by a cloned human ubiquitin-activating enzyme E1 of
RT   the S-phase-arrested mouse FM3A cell mutant with thermolabile E1.";
RL   Cell Struct. Funct. 17:113-122(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PROTEIN SEQUENCE OF 136-158;
RP   369-383; 417-430 AND 559-580, AND TISSUE SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=1986373; DOI=10.1073/pnas.88.1.258;
RA   Handley P.M., Mueckler M., Siegel N.R., Ciechanover A., Schwartz A.L.;
RT   "Molecular cloning, sequence, and tissue distribution of the human
RT   ubiquitin-activating enzyme E1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:258-262(1991).
RN   [3]
RP   ERRATUM.
RX   PubMed=1871145;
RA   Handley P.M., Mueckler M., Siegel N.R., Ciechanover A., Schwartz A.L.;
RL   Proc. Natl. Acad. Sci. U.S.A. 88:7456-7456(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 257-989.
RX   PubMed=2390975;
RA   Zacksenhaus E., Sheinin R.;
RT   "Molecular cloning, primary structure and expression of the human X
RT   linked A1S9 gene cDNA which complements the ts A1S9 mouse L cell
RT   defect in DNA replication.";
RL   EMBO J. 9:2923-2929(1990).
RN   [8]
RP   PROTEIN SEQUENCE OF 559-581 AND 924-944, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Brain, and Cajal-Retzius cell;
RA   Lubec G., Vishwanath V.;
RL   Submitted (MAR-2007) to UniProtKB.
RN   [9]
RP   FUNCTION, CATALYTIC ACTIVITY, ALTERNATIVE SPLICING, AND PATHWAY.
RX   PubMed=1447181;
RA   Cook J.C., Chock P.B.;
RT   "Isoforms of mammalian ubiquitin-activating enzyme.";
RL   J. Biol. Chem. 267:24315-24321(1992).
RN   [10]
RP   SUBCELLULAR LOCATION.
RX   PubMed=1376922; DOI=10.1073/pnas.89.12.5542;
RA   Schwartz A.L., Trausch J.S., Ciechanover A., Slot J.W., Geuze H.;
RT   "Immunoelectron microscopic localization of the ubiquitin-activating
RT   enzyme E1 in HepG2 cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:5542-5546(1992).
RN   [11]
RP   SUBCELLULAR LOCATION, AND CHARACTERIZATION OF ISOFORM 1 AND ISOFORM 2.
RX   PubMed=7528747;
RA   Handley-Gearhart P.M., Stephen A.G., Trausch-Azar J.S.,
RA   Ciechanover A., Schwartz A.L.;
RT   "Human ubiquitin-activating enzyme, E1. Indication of potential
RT   nuclear and cytoplasmic subpopulations using epitope-tagged cDNA
RT   constructs.";
RL   J. Biol. Chem. 269:33171-33178(1994).
RN   [12]
RP   PHOSPHORYLATION AT SER-4, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   SER-4 AND 8-LYS--ARG-11.
RX   PubMed=9099746; DOI=10.1074/jbc.272.16.10895;
RA   Stephen A.G., Trausch-Azar J.S., Handley-Gearhart P.M.,
RA   Ciechanover A., Schwartz A.L.;
RT   "Identification of a region within the ubiquitin-activating enzyme
RT   required for nuclear targeting and phosphorylation.";
RL   J. Biol. Chem. 272:10895-10903(1997).
RN   [13]
RP   ISGYLATION.
RX   PubMed=16139798; DOI=10.1016/j.bbrc.2005.08.132;
RA   Giannakopoulos N.V., Luo J.K., Papov V., Zou W., Lenschow D.J.,
RA   Jacobs B.S., Borden E.C., Li J., Virgin H.W., Zhang D.E.;
RT   "Proteomic identification of proteins conjugated to ISG15 in mouse and
RT   human cells.";
RL   Biochem. Biophys. Res. Commun. 336:496-506(2005).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer
RT   cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [15]
RP   INTERACTION WITH GAN.
RX   PubMed=16227972; DOI=10.1038/nature04256;
RA   Allen E., Ding J., Wang W., Pramanik S., Chou J., Yau V., Yang Y.;
RT   "Gigaxonin-controlled degradation of MAP1B light chain is critical to
RT   neuronal survival.";
RL   Nature 438:224-228(2005).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-13; SER-46; THR-800 AND
RP   SER-835, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-46 AND SER-810, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-671 AND LYS-980, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-46 AND SER-810, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-46, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [23]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=22456334; DOI=10.4161/cc.19978;
RA   Moudry P., Lukas C., Macurek L., Hanzlikova H., Hodny Z., Lukas J.,
RA   Bartek J.;
RT   "Ubiquitin-activating enzyme UBA1 is required for cellular response to
RT   DNA damage.";
RL   Cell Cycle 11:1573-1582(2012).
RN   [24]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, ACETYLATION [LARGE SCALE
RP   ANALYSIS] AT ALA-2 (ISOFORM 2), CLEAVAGE OF INITIATOR METHIONINE
RP   [LARGE SCALE ANALYSIS], CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE
RP   ANALYSIS] (ISOFORM 2), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-46 AND SER-835, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-820, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 1-439.
RX   PubMed=25209502; DOI=10.1080/09168451.2014.923301;
RA   Xie S.T.;
RT   "Expression, purification, and crystal structure of N-terminal domains
RT   of human ubiquitin-activating enzyme (E1).";
RL   Biosci. Biotechnol. Biochem. 78:1542-1549(2014).
RN   [29]
RP   VARIANTS SMAX2 ILE-539 AND GLY-547.
RX   PubMed=18179898; DOI=10.1016/j.ajhg.2007.09.009;
RA   Ramser J., Ahearn M.E., Lenski C., Yariz K.O., Hellebrand H.,
RA   von Rhein M., Clark R.D., Schmutzler R.K., Lichtner P., Hoffman E.P.,
RA   Meindl A., Baumbach-Reardon L.;
RT   "Rare missense and synonymous variants in UBE1 are associated with X-
RT   linked infantile spinal muscular atrophy.";
RL   Am. J. Hum. Genet. 82:188-193(2008).
RN   [30]
RP   VARIANT SMAX2 VAL-557.
RX   PubMed=23518311; DOI=10.1016/j.nmd.2013.02.001;
RA   Dlamini N., Josifova D.J., Paine S.M., Wraige E., Pitt M.,
RA   Murphy A.J., King A., Buk S., Smith F., Abbs S., Sewry C.,
RA   Jacques T.S., Jungbluth H.;
RT   "Clinical and neuropathological features of X-linked spinal muscular
RT   atrophy (SMAX2) associated with a novel mutation in the UBA1 gene.";
RL   Neuromuscul. Disord. 23:391-398(2013).
CC   -!- FUNCTION: Catalyzes the first step in ubiquitin conjugation to
CC       mark cellular proteins for degradation through the ubiquitin-
CC       proteasome system (PubMed:1606621, PubMed:1447181). Activates
CC       ubiquitin by first adenylating its C-terminal glycine residue with
CC       ATP, and thereafter linking this residue to the side chain of a
CC       cysteine residue in E1, yielding a ubiquitin-E1 thioester and free
CC       AMP (PubMed:1447181). Essential for the formation of radiation-
CC       induced foci, timely DNA repair and for response to replication
CC       stress. Promotes the recruitment of TP53BP1 and BRCA1 at DNA
CC       damage sites (PubMed:22456334). {ECO:0000269|PubMed:1447181,
CC       ECO:0000269|PubMed:1606621, ECO:0000269|PubMed:22456334}.
CC   -!- CATALYTIC ACTIVITY: ATP + ubiquitin + [E1 ubiquitin-activating
CC       enzyme]-L-cysteine = AMP + diphosphate + S-ubiquitinyl-[E1
CC       ubiquitin-activating enzyme]-L-cysteine.
CC       {ECO:0000305|PubMed:1447181}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:1447181, ECO:0000269|PubMed:1606621}.
CC   -!- SUBUNIT: Monomer (By similarity). Interacts with GAN (via BTB
CC       domain). {ECO:0000250, ECO:0000269|PubMed:16227972}.
CC   -!- INTERACTION:
CC       Q76353:- (xeno); NbExp=2; IntAct=EBI-709688, EBI-6248077;
CC       Q9H2C0:GAN; NbExp=5; IntAct=EBI-709688, EBI-764342;
CC       P63279:UBE2I; NbExp=2; IntAct=EBI-709688, EBI-80168;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:1376922}.
CC       Mitochondrion {ECO:0000269|PubMed:1376922}. Nucleus
CC       {ECO:0000269|PubMed:1376922, ECO:0000269|PubMed:22456334}.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Nucleus
CC       {ECO:0000269|PubMed:7528747, ECO:0000269|PubMed:9099746}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm
CC       {ECO:0000269|PubMed:7528747}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative initiation; Named isoforms=2;
CC       Name=1; Synonyms=E1a;
CC         IsoId=P22314-1; Sequence=Displayed;
CC       Name=2; Synonyms=E1b;
CC         IsoId=P22314-2; Sequence=VSP_055913;
CC         Note=Initiator Met-1 is removed. Contains a N-acetylalanine at
CC         position 2. {ECO:0000244|PubMed:22814378};
CC   -!- TISSUE SPECIFICITY: Detected in erythrocytes (at protein level).
CC       Ubiquitous. {ECO:0000269|PubMed:1986373}.
CC   -!- DOMAIN: The first 11 amino acids are essential for phosphorylation
CC       and exclusive nuclear localization.
CC   -!- PTM: ISGylated. {ECO:0000269|PubMed:16139798}.
CC   -!- DISEASE: Spinal muscular atrophy X-linked 2 (SMAX2) [MIM:301830]:
CC       A lethal infantile form of spinal muscular atrophy, a
CC       neuromuscular disorder characterized by degeneration of the
CC       anterior horn cells of the spinal cord, leading to symmetrical
CC       muscle weakness and atrophy. Clinical features include hypotonia,
CC       areflexia, and multiple congenital contractures.
CC       {ECO:0000269|PubMed:18179898, ECO:0000269|PubMed:23518311}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: There are two active sites within the E1 molecule,
CC       allowing it to accommodate two ubiquitin moieties at a time, with
CC       a new ubiquitin forming an adenylate intermediate as the previous
CC       one is transferred to the thiol site.
CC       {ECO:0000250|UniProtKB:P22515}.
CC   -!- SIMILARITY: Belongs to the ubiquitin-activating E1 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X56976; CAA40296.1; -; mRNA.
DR   EMBL; M58028; AAA61246.1; -; mRNA.
DR   EMBL; AL513366; CAI41708.1; -; Genomic_DNA.
DR   EMBL; CH471164; EAW59290.1; -; Genomic_DNA.
DR   EMBL; BC013041; AAH13041.1; -; mRNA.
DR   EMBL; X52897; CAA37078.1; -; mRNA.
DR   CCDS; CCDS14275.1; -. [P22314-1]
DR   PIR; A38564; A38564.
DR   RefSeq; NP_003325.2; NM_003334.3. [P22314-1]
DR   RefSeq; NP_695012.1; NM_153280.2. [P22314-1]
DR   RefSeq; XP_016885269.1; XM_017029780.1. [P22314-1]
DR   RefSeq; XP_016885270.1; XM_017029781.1. [P22314-1]
DR   UniGene; Hs.533273; -.
DR   PDB; 4P22; X-ray; 2.75 A; A/B=1-439.
DR   PDBsum; 4P22; -.
DR   ProteinModelPortal; P22314; -.
DR   SMR; P22314; -.
DR   BioGrid; 113165; 137.
DR   DIP; DIP-33686N; -.
DR   IntAct; P22314; 122.
DR   MINT; MINT-1130980; -.
DR   STRING; 9606.ENSP00000338413; -.
DR   BindingDB; P22314; -.
DR   ChEMBL; CHEMBL5924; -.
DR   DrugBank; DB04119; Hexatantalum Dodecabromide.
DR   iPTMnet; P22314; -.
DR   PhosphoSitePlus; P22314; -.
DR   SwissPalm; P22314; -.
DR   BioMuta; UBA1; -.
DR   DMDM; 24418865; -.
DR   REPRODUCTION-2DPAGE; IPI00645078; -.
DR   EPD; P22314; -.
DR   MaxQB; P22314; -.
DR   PaxDb; P22314; -.
DR   PeptideAtlas; P22314; -.
DR   PRIDE; P22314; -.
DR   DNASU; 7317; -.
DR   Ensembl; ENST00000335972; ENSP00000338413; ENSG00000130985. [P22314-1]
DR   Ensembl; ENST00000377351; ENSP00000366568; ENSG00000130985. [P22314-1]
DR   GeneID; 7317; -.
DR   KEGG; hsa:7317; -.
DR   UCSC; uc004dhj.5; human. [P22314-1]
DR   CTD; 7317; -.
DR   DisGeNET; 7317; -.
DR   GeneCards; UBA1; -.
DR   GeneReviews; UBA1; -.
DR   HGNC; HGNC:12469; UBA1.
DR   HPA; CAB019435; -.
DR   HPA; CAB073410; -.
DR   HPA; HPA000289; -.
DR   HPA; HPA001506; -.
DR   MalaCards; UBA1; -.
DR   MIM; 301830; phenotype.
DR   MIM; 314370; gene.
DR   neXtProt; NX_P22314; -.
DR   OpenTargets; ENSG00000130985; -.
DR   Orphanet; 1145; X-linked distal arthrogryposis multiplex congenita.
DR   PharmGKB; PA37119; -.
DR   eggNOG; KOG2012; Eukaryota.
DR   eggNOG; COG0476; LUCA.
DR   GeneTree; ENSGT00390000016689; -.
DR   HOGENOM; HOG000167329; -.
DR   HOVERGEN; HBG054199; -.
DR   InParanoid; P22314; -.
DR   KO; K03178; -.
DR   OMA; FISCESR; -.
DR   OrthoDB; EOG091G0130; -.
DR   PhylomeDB; P22314; -.
DR   TreeFam; TF300586; -.
DR   BioCyc; MetaCyc:HS05465-MONOMER; -.
DR   BRENDA; 2.3.2.B5; 2681.
DR   BRENDA; 6.2.1.B9; 2681.
DR   Reactome; R-HSA-8866652; Synthesis of active ubiquitin: roles of E1 and E2 enzymes.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   SIGNOR; P22314; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; UBA1; human.
DR   GeneWiki; UBA1; -.
DR   GenomeRNAi; 7317; -.
DR   PRO; PR:P22314; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000130985; -.
DR   CleanEx; HS_UBA1; -.
DR   ExpressionAtlas; P22314; baseline and differential.
DR   Genevisible; P22314; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0004839; F:ubiquitin activating enzyme activity; IDA:MGI.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; TAS:Reactome.
DR   InterPro; IPR032420; E1_4HB.
DR   InterPro; IPR032418; E1_FCCH.
DR   InterPro; IPR000594; ThiF_NAD_FAD-bd.
DR   InterPro; IPR018965; Ub-activating_enz_E1_C.
DR   InterPro; IPR019572; UBA_E1_Cys.
DR   InterPro; IPR018075; UBQ-activ_enz_E1.
DR   InterPro; IPR018074; UBQ-activ_enz_E1_CS.
DR   InterPro; IPR033127; UBQ-activ_enz_E1_Cys_AS.
DR   InterPro; IPR000011; UBQ/SUMO-activ_enz_E1-like.
DR   Pfam; PF16191; E1_4HB; 1.
DR   Pfam; PF16190; E1_FCCH; 1.
DR   Pfam; PF09358; E1_UFD; 1.
DR   Pfam; PF00899; ThiF; 2.
DR   Pfam; PF10585; UBA_e1_thiolCys; 1.
DR   PRINTS; PR01849; UBIQUITINACT.
DR   SMART; SM00985; UBA_e1_C; 1.
DR   SUPFAM; SSF69572; SSF69572; 2.
DR   TIGRFAMs; TIGR01408; Ube1; 1.
DR   PROSITE; PS00536; UBIQUITIN_ACTIVAT_1; 1.
DR   PROSITE; PS00865; UBIQUITIN_ACTIVAT_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative initiation; ATP-binding;
KW   Complete proteome; Cytoplasm; Direct protein sequencing;
KW   Disease mutation; Ligase; Mitochondrion; Neurodegeneration;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Ubl conjugation; Ubl conjugation pathway.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22814378}.
FT   CHAIN         2   1058       Ubiquitin-like modifier-activating enzyme
FT                                1.
FT                                /FTId=PRO_0000194934.
FT   REPEAT       63    199       1-1.
FT   REPEAT      459    611       1-2.
FT   NP_BIND     576    577       ATP. {ECO:0000250|UniProtKB:P22515}.
FT   REGION       63    611       2 approximate repeats.
FT   MOTIF         5     11       Nuclear localization signal.
FT   ACT_SITE    632    632       Glycyl thioester intermediate.
FT                                {ECO:0000255|PROSITE-ProRule:PRU10132}.
FT   BINDING     478    478       ATP; via amide nitrogen.
FT                                {ECO:0000250|UniProtKB:P22515}.
FT   BINDING     504    504       ATP. {ECO:0000250|UniProtKB:P22515}.
FT   BINDING     515    515       ATP. {ECO:0000250|UniProtKB:P22515}.
FT   BINDING     528    528       ATP. {ECO:0000250|UniProtKB:P22515}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES       4      4       Phosphoserine.
FT                                {ECO:0000269|PubMed:9099746}.
FT   MOD_RES      13     13       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES      21     21       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q02053}.
FT   MOD_RES      24     24       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q02053}.
FT   MOD_RES      46     46       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES      55     55       Phosphotyrosine.
FT                                {ECO:0000250|UniProtKB:Q02053}.
FT   MOD_RES     528    528       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:Q02053}.
FT   MOD_RES     671    671       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     800    800       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     810    810       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231}.
FT   MOD_RES     816    816       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q02053}.
FT   MOD_RES     820    820       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     835    835       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     980    980       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   VAR_SEQ       1     40       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_055913.
FT   VARIANT     447    447       R -> H (in dbSNP:rs2070169).
FT                                /FTId=VAR_043500.
FT   VARIANT     539    539       M -> I (in SMAX2; dbSNP:rs80356545).
FT                                {ECO:0000269|PubMed:18179898}.
FT                                /FTId=VAR_043501.
FT   VARIANT     547    547       S -> G (in SMAX2; dbSNP:rs80356546).
FT                                {ECO:0000269|PubMed:18179898}.
FT                                /FTId=VAR_043502.
FT   VARIANT     557    557       E -> V (in SMAX2).
FT                                {ECO:0000269|PubMed:23518311}.
FT                                /FTId=VAR_071121.
FT   MUTAGEN       4      4       S->A: Reduces phosphorylation.
FT                                {ECO:0000269|PubMed:9099746}.
FT   MUTAGEN       8     11       KKRR->AAAA: Loss of nuclear localization
FT                                and a 90-95% decrease in the
FT                                phosphorylation.
FT                                {ECO:0000269|PubMed:9099746}.
FT   CONFLICT    190    190       D -> G (in Ref. 1; CAA40296).
FT                                {ECO:0000305}.
FT   CONFLICT    434    434       E -> Q (in Ref. 1; CAA40296).
FT                                {ECO:0000305}.
FT   HELIX        55     62       {ECO:0000244|PDB:4P22}.
FT   STRAND       74     78       {ECO:0000244|PDB:4P22}.
FT   HELIX        82     93       {ECO:0000244|PDB:4P22}.
FT   STRAND       97    102       {ECO:0000244|PDB:4P22}.
FT   HELIX       109    112       {ECO:0000244|PDB:4P22}.
FT   HELIX       120    122       {ECO:0000244|PDB:4P22}.
FT   HELIX       127    136       {ECO:0000244|PDB:4P22}.
FT   STRAND      140    142       {ECO:0000244|PDB:4P22}.
FT   STRAND      144    147       {ECO:0000244|PDB:4P22}.
FT   HELIX       153    156       {ECO:0000244|PDB:4P22}.
FT   STRAND      160    164       {ECO:0000244|PDB:4P22}.
FT   HELIX       169    181       {ECO:0000244|PDB:4P22}.
FT   STRAND      185    192       {ECO:0000244|PDB:4P22}.
FT   STRAND      195    201       {ECO:0000244|PDB:4P22}.
FT   STRAND      206    210       {ECO:0000244|PDB:4P22}.
FT   STRAND      219    224       {ECO:0000244|PDB:4P22}.
FT   STRAND      226    229       {ECO:0000244|PDB:4P22}.
FT   STRAND      231    234       {ECO:0000244|PDB:4P22}.
FT   STRAND      244    252       {ECO:0000244|PDB:4P22}.
FT   HELIX       257    259       {ECO:0000244|PDB:4P22}.
FT   STRAND      265    269       {ECO:0000244|PDB:4P22}.
FT   STRAND      271    273       {ECO:0000244|PDB:4P22}.
FT   STRAND      291    301       {ECO:0000244|PDB:4P22}.
FT   HELIX       306    311       {ECO:0000244|PDB:4P22}.
FT   HELIX       326    343       {ECO:0000244|PDB:4P22}.
FT   HELIX       352    368       {ECO:0000244|PDB:4P22}.
FT   TURN        371    373       {ECO:0000244|PDB:4P22}.
FT   HELIX       380    388       {ECO:0000244|PDB:4P22}.
FT   HELIX       395    413       {ECO:0000244|PDB:4P22}.
FT   STRAND      422    428       {ECO:0000244|PDB:4P22}.
SQ   SEQUENCE   1058 AA;  117849 MW;  4B413AAA75FAA562 CRC64;
     MSSSPLSKKR RVSGPDPKPG SNCSPAQSVL SEVPSVPTNG MAKNGSEADI DEGLYSRQLY
     VLGHEAMKRL QTSSVLVSGL RGLGVEIAKN IILGGVKAVT LHDQGTAQWA DLSSQFYLRE
     EDIGKNRAEV SQPRLAELNS YVPVTAYTGP LVEDFLSGFQ VVVLTNTPLE DQLRVGEFCH
     NRGIKLVVAD TRGLFGQLFC DFGEEMILTD SNGEQPLSAM VSMVTKDNPG VVTCLDEARH
     GFESGDFVSF SEVQGMVELN GNQPMEIKVL GPYTFSICDT SNFSDYIRGG IVSQVKVPKK
     ISFKSLVASL AEPDFVVTDF AKFSRPAQLH IGFQALHQFC AQHGRPPRPR NEEDAAELVA
     LAQAVNARAL PAVQQNNLDE DLIRKLAYVA AGDLAPINAF IGGLAAQEVM KACSGKFMPI
     MQWLYFDALE CLPEDKEVLT EDKCLQRQNR YDGQVAVFGS DLQEKLGKQK YFLVGAGAIG
     CELLKNFAMI GLGCGEGGEI IVTDMDTIEK SNLNRQFLFR PWDVTKLKSD TAAAAVRQMN
     PHIRVTSHQN RVGPDTERIY DDDFFQNLDG VANALDNVDA RMYMDRRCVY YRKPLLESGT
     LGTKGNVQVV IPFLTESYSS SQDPPEKSIP ICTLKNFPNA IEHTLQWARD EFEGLFKQPA
     ENVNQYLTDP KFVERTLRLA GTQPLEVLEA VQRSLVLQRP QTWADCVTWA CHHWHTQYSN
     NIRQLLHNFP PDQLTSSGAP FWSGPKRCPH PLTFDVNNPL HLDYVMAAAN LFAQTYGLTG
     SQDRAAVATF LQSVQVPEFT PKSGVKIHVS DQELQSANAS VDDSRLEELK ATLPSPDKLP
     GFKMYPIDFE KDDDSNFHMD FIVAASNLRA ENYDIPSADR HKSKLIAGKI IPAIATTTAA
     VVGLVCLELY KVVQGHRQLD SYKNGFLNLA LPFFGFSEPL AAPRHQYYNQ EWTLWDRFEV
     QGLQPNGEEM TLKQFLDYFK TEHKLEITML SQGVSMLYSF FMPAAKLKER LDQPMTEIVS
     RVSKRKLGRH VRALVLELCC NDESGEDVEV PYVRYTIR
//
